Search Results 3321-3330 of 22485 for oral

  1. Mayo Clinic expert explains gastrointestinal symptoms related to COVID-19

    ... oral spread. At this time, we don't know for sure if there is fecal-oral spread or not. But with caution, I think we should assume that if there is somebody ...

  3. Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk Myelodysplastic Syndromes - Mayo Clinic

    ... (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal ...

  4. Methylprednisolone (injection route) - Mayo Clinic

    Your doctor may give you a few doses of this medicine until your condition improves, and then switch you to an oral medicine that works the same way. If you ...

  5. A One-Time DNA Study for Vasculitis - Mayo Clinic

    Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood; Abnormal chest radiograph with nodules, fixed infiltrates, or cavities ...

  6. Mayo Clinic Q and A: Immunotherapy and breast cancer

    When patients develop side effects, depending on the severity of the side effects, the immunotherapy drug may need to be withheld, and sometimes oral ...

  7. A Study to Evaluate Effectiveness and Safety of Ustekinumab Re-induction Therapy in Participants With Moderate to Severely Active Crohn's Disease (POWER) - Mayo Clinic

    Oral 5-aminosalicylic acid (5-ASA) compounds;; Oral corticosteroids (e.g., prednisone, budesonide) at a prednisone-equivalent dose of ≤ 40 mg/day or ≤ 9 mg ...

  8. Study of VS-6766 + Adagrasib in KRAS G12C NSCLC Patients - Mayo Clinic

    Patients on warfarin for deep vein thrombosis/pulmonary embolism can be converted to low-molecular-weight heparin or direct oral anticoagulants. Prior ...

  9. Joaquin Sanchez-Sotelo, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    2019 First Award for Oral Presentation at 20th General Meeting ISOLS 2019 for "Comparison of Reconstructive Techniques Following Oncologic Intraarticular ...

  10. Study of MK-8242 Alone and in Combination with Cytarabine in Participants with Acute Myelogenous Leukemia (P07649) - Mayo Clinic

    Must be able to swallow, retain, and absorb oral medications and oral nutrition; Must follow the appropriate washout period for prohibited treatments.